IR
55
-6
VRTX
43
-4
LB
38
-3
RL
66
-2
MA
58
3
KIM
66
2
ZTS
36
7
DUK
37
-3
FSLR
57
8
TEL
66
16
INTC
36
8
NOV
49
-3
GPC
22
-3
VZ
34
-3
MTB
56
-3
DTE
45
-2
KR
40
3
TMO
51
4
JNPR
59
3
PM
60
-8
IR
55
-6
VRTX
43
-4
LB
38
-3
RL
66
-2
MA
58
3
KIM
66
2
ZTS
36
7
DUK
37
-3
FSLR
57
8
TEL
66
16
INTC
36
8
NOV
49
-3
GPC
22
-3
VZ
34
-3
MTB
56
-3
DTE
45
-2
KR
40
3
TMO
51
4
JNPR
59
3
PM
60
-8
Financhill
Back

BioXcel Therapeutics 10K Form

Sell
41

BTAI
BioXcel Therapeutics

Last Price:
0.64
Seasonality Move:
71.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BTAI News And Ratings

See the #1 stock for the next 7 days that we like better than BTAI

BTAI Financial Statistics

Sales & Book Value

Annual Sales: $1.38M
Cash Flow: $-23.17M
Price / Cash Flow: 0
Annual Sales: $-1.84
Price / Book: 0

Profitability

EPS (TTM): -3.56000
Net Income (TTM): $-107.83M
Gross Margin: $120K
Return on Equity: 0%
Return on Assets: -116.7%

BioXcel Therapeutics Earnings Forecast

Key BioXcel Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for BTAI is 8.70%.
  • The Selling, General & Administrative Expenses for BTAI have been equal to 6,044.42% of Gross Profit Margin.
  • The Research & Development expenses have been 6,110.58% of Revenue.
  • The Interest Expense is -7.44% of Operating Income.
  • The Net Earning history of BTAI is -12,974.86% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 0 years.

BioXcel Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BTAI
CUSIP: 09075P
Website: bioxceltherapeutics.com

Debt

Debt-to-Equity Ratio: -1.39
Current Ratio: 2.35
Quick Ratio: 2.09

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BTAI Technical Analysis vs Fundamental Analysis

Sell
41
BioXcel Therapeutics (BTAI) is a Sell

Is BioXcel Therapeutics a Buy or a Sell?